Enterprise Value
1.288B
Cash
561.5M
Avg Qtr Burn
-53.02M
Short % of Float
10.16%
Insider Ownership
1.29%
Institutional Own.
-
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
FILSPARI (Sparsentan) Details Kidney disease, IgA nephropathy | Approved Quarterly sales | |
THIOLA® EC (tiopronin) Details Cystinuria | Approved Quarterly sales | |
CDCA (Chenodal/ chenodeoxycholic acid) Details Cerebrotendinous xanthomatosis | Phase 3 Data readout | |
FILSPARI (Sparsentan) Details IgA nephropathy, Kidney disease | Phase 3 Data readout | |
Sparsentan Details Kidney disease, Focal segmental glomerulosclerosis | Phase 3 Update | |
Pegtibatinase (TVT-058) Details Homocystinuria | Phase 3 Initiation |